Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Delaloge, S.; Cella, D.; Ye, Y.; Buyse, M.; Chan, A.; Barrios, C. H.; Holmes, F. A.; Mansi, J.; Iwata, H.; Ejlertsen, B.; Moy, B.; Chia, S. K. L.; Gnant, M.; Smichkoska, S.; Ciceniene, A.; Martinez, N.; Filipović, S.; Ben-Baruch, N. E.; Joy, A. A.; Langkjer, S. T.; Senecal, F.; de Boer, R. H.; Moran, S.; Yao, B.; Bryce, R.; Auerbach, A.; Fallowfield, L.; Martin, M.

Published in

Elsevier, Annals of Oncology, 4(30), p. 567-574, 2019

DOI: 10.1093/annonc/mdz016

Tools

Export citation

Search in Google Scholar

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Journal article published in 2019 by S. Delaloge, D. Cella, Y. Ye, M. Buyse, A. Chan, C. H. Barrios, F. A. Holmes, J. Mansi, H. Iwata, B. Ejlertsen, B. Moy, S. K. L. Chia, M. Gnant, S. Smichkoska, A. Ciceniene and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial